These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29668829)

  • 1. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene.
    Brahmi M; Alberti L; Tirode F; Karanian M; Eberst L; Pissaloux D; Cassier P; Blay JY
    Ann Oncol; 2018 Jun; 29(6):1488-1489. PubMed ID: 29668829
    [No Abstract]   [Full Text] [Related]  

  • 2. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
    West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors.
    Möller E; Mandahl N; Mertens F; Panagopoulos I
    Genes Chromosomes Cancer; 2008 Jan; 47(1):21-5. PubMed ID: 17918257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors.
    Panagopoulos I; Brandal P; Gorunova L; Bjerkehagen B; Heim S
    Int J Oncol; 2014 May; 44(5):1425-32. PubMed ID: 24604026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer.
    Okugawa Y; Toiyama Y; Ichikawa T; Kawamura M; Yasuda H; Fujikawa H; Saigusa S; Ohi M; Araki T; Tanaka K; Inoue Y; Tanaka M; Miki C; Kusunoki M
    Int J Oncol; 2018 Aug; 53(2):737-749. PubMed ID: 29767252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
    N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
    Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
    Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel
    Mejbel H; Siegal GP; Wei S
    Int J Surg Pathol; 2022 May; 30(3):335-338. PubMed ID: 34657489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
    Smeester BA; Slipek NJ; Pomeroy EJ; Laoharawee K; Osum SH; Larsson AT; Williams KB; Stratton N; Yamamoto K; Peterson JJ; Rathe SK; Mills LJ; Hudson WA; Crosby MR; Wang M; Rahrmann EP; Moriarity BS; Largaespada DA
    Bone; 2020 Jul; 136():115353. PubMed ID: 32251854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
    Cannarile MA; Weisser M; Jacob W; Jegg AM; Ries CH; Rüttinger D
    J Immunother Cancer; 2017 Jul; 5(1):53. PubMed ID: 28716061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF1R Ligands IL-34 and CSF1 Are Differentially Required for Microglia Development and Maintenance in White and Gray Matter Brain Regions.
    Easley-Neal C; Foreman O; Sharma N; Zarrin AA; Weimer RM
    Front Immunol; 2019; 10():2199. PubMed ID: 31616414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
    Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.